News
Harbour Co-Founds Cancer Startup, Hands Off Clinical-Stage Antibody
1+ hour, 26+ min ago (307+ words) Chinese biotech Harbour BioMed is taking part in the formation of Solstice Oncology alongside a group of unnamed venture capital investors, giving the startup exclusive global access to its lead asset HBM4003. Under the terms of Tuesday's deal, Harbour will receive…...
Patient Death Forces Partial Freeze on MacroGenics’ Gynecologic Cancer Study
1+ hour, 37+ min ago (451+ words) A patient has died in a mid-stage study of MacroGenics" bispecific antibody lorigerlimab in gynecologic cancers, prompting the FDA to slap a partial clinical hold on the trial. The patient in question developed grade 4 neutropenia and concurrent septic shock, the…...
Slate, Alveus Raise Hefty Series A Hauls for Migraine, Obesity Drugs
1+ hour, 49+ min ago (392+ words) Tuesday turned out to be a busy day for biotech, with migraine developer Slate Medicines and obesity player Alveus Therapeutics closing their respective series A rounds with more than $100 million in proceeds each. With $130 million in fresh funds, Slate is…...
Segmed Partners with Verily to Expand Access to Real-World Imaging Data
2+ hour, 30+ min ago (362+ words) Segmed Partners with Verily to Expand Access to Real-World Imaging Data'BioSpace Segmed Partners with Verily to Expand Access to Real-World Imaging Data Segmed imaging datasets will soon be available within Verily's secure, self-serve AI-native platform to support precision health research…...
Abram Scientific Secures $11.75M Series A Funding Led by Octapharma AG
2+ hour, 31+ min ago (551+ words) Abram Scientific Secures $11.75M Series A Funding Led by Octapharma AG'BioSpace Abram Scientific Secures $11.75M Series A Funding Led by Octapharma AG Financing will accelerate the development of proprietary portable diagnostic platform, CoagCare, to enhance patient care for bleeding disorders & critical care…...
Lilly Bests Novo Again, Rare Disease Week Goes Regulatory, More CDC Leadership Upheaval
3+ hour ago (322+ words) Lilly Bests Novo Again, Rare Disease Week Goes Regulatory, More CDC Leadership Upheaval'BioSpace Eli Lilly notches another win over Novo Nordisk, as Zepbound bests CagriSema in a head-to-head trial sponsored by Novo; The FDA kicked off Rare Disease Week, providing…...
Galderma Announces Triple Approval of New State-of-the-Art Restylane® Syringe in the EU, the U.S., and Canada, Reaffirming the Company’s Position at the Forefront of Injectable Aesthetics
4+ hour, 57+ min ago (649+ words) ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD), today announced that regulatory authorities in the EU, the U.S., and Canada have approved a new state-of-the-art syringe for use with its NASHA" lidocaine range of Restylane products in multiple facial indications including the…...
Zimmer Biomet to Release New Data, Highlight Key Innovations at American Academy of Orthopaedic Surgeons Annual Meeting
5+ hour, 1+ min ago (264+ words) On Thursday, March 5 at 10:30 a.m. Central Time, Schwarzenegger will be featured as the Presidential Guest Speaker, and will join Zimmer Biomet Chairman, President and CEO Ivan Tornos and AAOS President Ned Amendola, MD, FAAOS, FRCSC, DABOS, for a main-stage conversation about…...
Itovebi® (inavolisib) marks milestone as the first breast cancer treatment funded through Ontario's new faster access program
6+ hour, 1+ min ago (356+ words) The Canada's Drug Agency issued a final positive recommendation for the treatment on December 15, 2025.10 Roche Canada is committed to working with all jurisdictions and the pan-Canadian Pharmaceutical Alliance (pCPA) to ensure patients outside of Ontario can also access Itovebi as…...
MiraDx Launches New Genetic Test Expanding Radiation Therapy Risk Assessment for Prostate Cancer Patients
6+ hour, 25+ min ago (636+ words) MiraDx Launches New Genetic Test Expanding Radiation Therapy Risk Assessment for Prostate Cancer Patients'BioSpace MiraDx Launches New Genetic Test Expanding Radiation Therapy Risk Assessment for Prostate Cancer Patients PROSTOX" Standard test predicts long-term urinary side effects from radiation therapy, identifying…...